Raquel Gil-Gouveia1,2, Inês Brás Marques3, Elsa Paixão Parreira3, Isabel Pavão Martins4,5, António Gouveia Oliveira6. 1. Hospital da Luz Headache Center, Hospital da Luz, Lisboa, Avenida Lusíada n 100, 1500-650, Lisbon, Portugal. rgilgouveia@gmail.com. 2. Headache Outpatient Clinic, Hospital de Santa Maria, Lisbon, Portugal. rgilgouveia@gmail.com. 3. Hospital da Luz Headache Center, Hospital da Luz, Lisboa, Avenida Lusíada n 100, 1500-650, Lisbon, Portugal. 4. Headache Outpatient Clinic, Hospital de Santa Maria, Lisbon, Portugal. 5. Lisbon Faculty of Medicine, University of Lisbon, Lisbon, Portugal. 6. Pharmacy Department, Universidade Federal do Rio Grande do Norte, Natal, Brazil.
Abstract
BACKGROUND: This study aimed to validate a semi-quantitative composite score tool, "Headache Gauge" (HG), to monitor the treatment effect in primary headaches in everyday clinic practice, adjustable to any chosen timeframe. METHOD: A cohort validation study of HG was performed in primary headache patients, recovering their clinical data and patient-related outcome measures (PROMs) for headache (HIT-6, MIDAS, HURT), work impact (WPAIQ), quality-of-life (SF-12), and mood (STAI, ZUNG). HG score distribution, its relation to clinical variables, its internal consistency, and its convergent validity were determined. RESULTS: HG was plotted in 233 patients: 90.1% females, age average 37 years, 86% with migraine, 27% with chronic headaches, and 28% with medication overuse. HG ranged from 0.21 to 58.3 in this sample, higher in chronic headaches (HG 16) and medication overuse (HG 15). HG presented good concurrent validity, significantly correlating with HIT-6 (p < 0.0001), SF-12 (p = 0.001), WPAIQ (p < 0.0001), MIDAS (p < 0.0001), and HURT (p < 0.0001). Good sensitivity to change (p < 0.001) and moderate test-retest reliability (p = 0.001) were calculated after reassessment of 147 patients (63.1% of the initial sample). CONCLUSIONS: Headache Gauge is a clinical data-based outcome measure that conceptually translates the percentage of lost time to headache in any given timeframe. It relates to headache impact, therefore bearing the potential to be relevant in real-life clinical monitoring.
BACKGROUND: This study aimed to validate a semi-quantitative composite score tool, "Headache Gauge" (HG), to monitor the treatment effect in primary headaches in everyday clinic practice, adjustable to any chosen timeframe. METHOD: A cohort validation study of HG was performed in primary headachepatients, recovering their clinical data and patient-related outcome measures (PROMs) for headache (HIT-6, MIDAS, HURT), work impact (WPAIQ), quality-of-life (SF-12), and mood (STAI, ZUNG). HG score distribution, its relation to clinical variables, its internal consistency, and its convergent validity were determined. RESULTS: HG was plotted in 233 patients: 90.1% females, age average 37 years, 86% with migraine, 27% with chronic headaches, and 28% with medication overuse. HG ranged from 0.21 to 58.3 in this sample, higher in chronic headaches (HG 16) and medication overuse (HG 15). HG presented good concurrent validity, significantly correlating with HIT-6 (p < 0.0001), SF-12 (p = 0.001), WPAIQ (p < 0.0001), MIDAS (p < 0.0001), and HURT (p < 0.0001). Good sensitivity to change (p < 0.001) and moderate test-retest reliability (p = 0.001) were calculated after reassessment of 147 patients (63.1% of the initial sample). CONCLUSIONS:Headache Gauge is a clinical data-based outcome measure that conceptually translates the percentage of lost time to headache in any given timeframe. It relates to headache impact, therefore bearing the potential to be relevant in real-life clinical monitoring.
Authors: L M Bloudek; M Stokes; D C Buse; T K Wilcox; R B Lipton; P J Goadsby; S F Varon; A M Blumenfeld; Z Katsarava; J Pascual; M Lanteri-Minet; P Cortelli; P Martelletti Journal: J Headache Pain Date: 2012-05-29 Impact factor: 7.277
Authors: Hans-Christoph Diener; Cristina Tassorelli; David W Dodick; Stephen D Silberstein; Richard B Lipton; Messoud Ashina; Werner J Becker; Michel D Ferrari; Peter J Goadsby; Patricia Pozo-Rosich; Shuu-Jiun Wang; Jay Mandrekar Journal: Cephalalgia Date: 2019-02-26 Impact factor: 6.292